TSMC Q4 Net Profit Soars 35%, Igniting AI Demand Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 17 2026
0mins
Source: Benzinga
- TSMC Earnings Surprise: Taiwan Semiconductor Manufacturing Co. Ltd. reported a 35% year-over-year increase in net profit for Q4, exceeding market expectations and indicating robust AI demand, which boosted related tech stocks and enhanced investor confidence.
- Small-Cap Outperformance: Despite pressure on large caps, the Russell 2000 index reached new highs last week, reflecting strong earnings prospects for small-cap stocks supported by positive economic data, attracting increased investor interest.
- Market Sentiment Fluctuations: While bank earnings from Goldman Sachs and Morgan Stanley were strong, overall market performance remained volatile due to macro policy uncertainties, indicating a cautious investor outlook on future economic trends.
- Venus Concept Stock Surge: Venus Concept's stock skyrocketed over 500% after Madryn Asset Management disclosed a 91% stake, despite recent revenue declines, as investors expressed optimism about the company's strategic direction and upcoming product innovations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GS
Wall Street analysts forecast GS stock price to fall
12 Analyst Rating
5 Buy
7 Hold
0 Sell
Moderate Buy
Current: 1096.560
Low
604.00
Averages
951.45
High
1100
Current: 1096.560
Low
604.00
Averages
951.45
High
1100
About GS
The Goldman Sachs Group, Inc. is a global financial institution that delivers a range of financial services to a large and diversified client base that includes corporations, financial institutions, governments and individuals. Its segments include Global Banking & Markets, Asset & Wealth Management and Platform Solutions. The Global Banking & Markets segment offers a range of services, including financing, advisory services, risk distribution, and hedging for its institutional and corporate clients. It facilitates client transactions and makes markets in fixed income, equity, currency and commodity products. The Asset & Wealth Management segment manages assets and offers investment products across all asset classes to a diverse set of clients. It also provides investing and wealth advisory solutions. The Platform Solutions segment includes consumer platforms, such as partnerships offering credit cards and point-of-sale financing, and transaction banking and other platform businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Grail's Galleri Test Misses Key Endpoint in Landmark Trial
- Trial Results Disappoint: Grail's Galleri test missed its primary endpoint in the NHS trial, failing to demonstrate a statistically significant reduction in Stage III-IV cancers, which led to a more than 30% drop in stock price, although some investors remain optimistic about the potential for FDA approval.
- Follow-Up Data Potential: Management believes that 12-month follow-up data from the NHS trial may reveal undetected cancers in the control group, thereby supporting the Galleri test's efficacy in reducing late-stage cancer detection, which could influence insurers' coverage decisions.
- Focus on Deadly Cancers: The sensitivity for detecting 12 deadly cancers in the NHS trial was 54.7%, significantly higher than the overall sensitivity of 30.7%, which may encourage insurers to prioritize the cost-benefit analysis of these cancers over the broader 50+ cancers tested.
- Predictive Value Advantage: The positive predictive value (PPV) of the Galleri test was 52% in the NHS trial and 60.3% in PATHFINDER 2, indicating its effectiveness in cancer detection, which may attract insurers to consider expanding their coverage based on these results.
See More
Analysis of Earnings from Locking in High CD Rates
- Current CD Rate Overview: As of June 21, 2026, the highest CD rate is 4% APY offered by Marcus by Goldman Sachs for a 14-month CD, attracting more savers to lock in their funds and enhancing the bank's deposit base.
- Interest Earnings Calculation: For a $1,000 investment in a one-year CD at 1.52% APY, the year-end balance would be $1,015.20, illustrating the impact of compounding interest; choosing a 4% APY CD would increase the balance to $1,040.74, highlighting the direct effect of higher rates on savings growth.
- Deposit Amount and Earnings Relationship: If the investment amount is raised to $10,000 with a 4% APY CD, the final balance would reach $10,407.42, resulting in $407.42 in interest, emphasizing the positive correlation between deposit amounts and earnings, encouraging savers to consider larger deposits.
- Diversity of CD Types: Beyond traditional CDs, various types such as Bump-up CDs and No-penalty CDs exist, which may offer lower rates but provide flexibility for savers, catering to different investor needs and reflecting the trend of product diversification in the financial market.
See More
Wall Street Lowers Gold Outlook Amid Fed Hawkishness
- Fed Hawkish Impact: Following the hawkish tone of new Fed Chairman Kevin Warsh, several Wall Street firms have downgraded their gold price outlook, anticipating a significantly higher risk of rate hikes this year, which makes it difficult for gold to rise meaningfully in the near term.
- Target Price Adjustments: Bank of America has lowered its gold target from $6,000 to an unlikely figure due to an uncomfortable inflation backdrop that may drive tighter monetary policy, with gold prices currently at $4,207, reflecting market sensitivity to rate hike expectations.
- ETF Liquidity Risks: Morgan Stanley noted that the hawkish Fed stance brings fresh challenges for ETF buying, making their previous $5,200 gold target more challenging to achieve, as ETF flows are sensitive to changes in rate expectations and real yields.
- Other Firms' Reactions: Goldman Sachs has cut its year-end gold target from $5,400 to $4,900, indicating no rate cuts from the Fed before the second half of 2027, reflecting a cautious view on short-term downside risks and medium-term upside potential for gold.
See More
Marvell Technology Stock Soars 247% Amid AI Demand Surge
- Stock Surge: Marvell Technology's stock has surged 247% this year, driven by investor confidence in its ability to meet the skyrocketing demand for application-specific integrated circuits (ASICs) and networking equipment in AI data centers.
- Market Expectations: Despite a 12-month median price target of $240, which is below the current price of $307.36, Marvell's trailing P/E ratio of 106 indicates strong market expectations for its future profitability, reflecting investor confidence in its growth trajectory.
- Revenue Growth Forecast: Marvell anticipates a 40% revenue growth in fiscal 2027, reaching $11.5 billion, with a potential 50% growth in fiscal 2029, suggesting revenues could hit $25 billion, showcasing its robust growth potential amid ongoing data center investments.
- Market Opportunities: With the optical networking market projected to grow 9x to $154 billion, Marvell's pivotal role in this sector is expected to double its annual revenue from data center interconnect products to $1 billion between fiscal 2026 and 2028, further solidifying its position in AI infrastructure.
See More
QVML Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: QVML's 52-week low is $35.06 per share, with a high of $44.815, and the last trade at $44.40 indicates the stock is fluctuating near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess price trends and identify potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing significant inflows or outflows, allowing assessment of their impact on underlying assets, particularly during the creation or destruction of units.
See More
Market Dynamics and Corporate Mergers Overview
- Muted Market Start: The new trading week begins with the S&P 500 indicated flat while the tech-heavy Nasdaq shows slight gains, and WTI crude oil is trading around $76.50 per barrel, reflecting cautious market sentiment regarding economic outlook.
- Abbvie Acquires Apogee: Abbvie is acquiring Apogee Therapeutics for $10.9 billion to strengthen its immunology portfolio, particularly competing with Johnson & Johnson's Tremfya through its top drug Skyrizi, which is expected to enhance Abbvie's competitive edge in the biopharmaceutical market.
- CRH Acquires Arcosa: CRH is acquiring Arcosa for $8.5 billion, stating that the acquisition is highly complementary amid growing demand for energy and utility infrastructure, which is expected to further solidify CRH's position in the construction materials market.
- Estee Lauder Buy Rating Reinstated: Goldman Sachs has reinstated a buy rating for Estee Lauder with a price target of $100, as analysts believe the market is underestimating the company's growth momentum, especially after it walked away from merger talks with Spanish beauty peer Puig.
See More
Grail's Galleri Test Misses Key Endpoint in Landmark Trial
- Trial Results Disappoint: Grail's Galleri test missed its primary endpoint in the NHS trial, failing to demonstrate a statistically significant reduction in Stage III-IV cancers, which led to a more than 30% drop in stock price, although some investors remain optimistic about the potential for FDA approval.
- Follow-Up Data Potential: Management believes that 12-month follow-up data from the NHS trial may reveal undetected cancers in the control group, thereby supporting the Galleri test's efficacy in reducing late-stage cancer detection, which could influence insurers' coverage decisions.
- Focus on Deadly Cancers: The sensitivity for detecting 12 deadly cancers in the NHS trial was 54.7%, significantly higher than the overall sensitivity of 30.7%, which may encourage insurers to prioritize the cost-benefit analysis of these cancers over the broader 50+ cancers tested.
- Predictive Value Advantage: The positive predictive value (PPV) of the Galleri test was 52% in the NHS trial and 60.3% in PATHFINDER 2, indicating its effectiveness in cancer detection, which may attract insurers to consider expanding their coverage based on these results.
See More
Analysis of Earnings from Locking in High CD Rates
- Current CD Rate Overview: As of June 21, 2026, the highest CD rate is 4% APY offered by Marcus by Goldman Sachs for a 14-month CD, attracting more savers to lock in their funds and enhancing the bank's deposit base.
- Interest Earnings Calculation: For a $1,000 investment in a one-year CD at 1.52% APY, the year-end balance would be $1,015.20, illustrating the impact of compounding interest; choosing a 4% APY CD would increase the balance to $1,040.74, highlighting the direct effect of higher rates on savings growth.
- Deposit Amount and Earnings Relationship: If the investment amount is raised to $10,000 with a 4% APY CD, the final balance would reach $10,407.42, resulting in $407.42 in interest, emphasizing the positive correlation between deposit amounts and earnings, encouraging savers to consider larger deposits.
- Diversity of CD Types: Beyond traditional CDs, various types such as Bump-up CDs and No-penalty CDs exist, which may offer lower rates but provide flexibility for savers, catering to different investor needs and reflecting the trend of product diversification in the financial market.
See More
Wall Street Lowers Gold Outlook Amid Fed Hawkishness
- Fed Hawkish Impact: Following the hawkish tone of new Fed Chairman Kevin Warsh, several Wall Street firms have downgraded their gold price outlook, anticipating a significantly higher risk of rate hikes this year, which makes it difficult for gold to rise meaningfully in the near term.
- Target Price Adjustments: Bank of America has lowered its gold target from $6,000 to an unlikely figure due to an uncomfortable inflation backdrop that may drive tighter monetary policy, with gold prices currently at $4,207, reflecting market sensitivity to rate hike expectations.
- ETF Liquidity Risks: Morgan Stanley noted that the hawkish Fed stance brings fresh challenges for ETF buying, making their previous $5,200 gold target more challenging to achieve, as ETF flows are sensitive to changes in rate expectations and real yields.
- Other Firms' Reactions: Goldman Sachs has cut its year-end gold target from $5,400 to $4,900, indicating no rate cuts from the Fed before the second half of 2027, reflecting a cautious view on short-term downside risks and medium-term upside potential for gold.
See More
Marvell Technology Stock Soars 247% Amid AI Demand Surge
- Stock Surge: Marvell Technology's stock has surged 247% this year, driven by investor confidence in its ability to meet the skyrocketing demand for application-specific integrated circuits (ASICs) and networking equipment in AI data centers.
- Market Expectations: Despite a 12-month median price target of $240, which is below the current price of $307.36, Marvell's trailing P/E ratio of 106 indicates strong market expectations for its future profitability, reflecting investor confidence in its growth trajectory.
- Revenue Growth Forecast: Marvell anticipates a 40% revenue growth in fiscal 2027, reaching $11.5 billion, with a potential 50% growth in fiscal 2029, suggesting revenues could hit $25 billion, showcasing its robust growth potential amid ongoing data center investments.
- Market Opportunities: With the optical networking market projected to grow 9x to $154 billion, Marvell's pivotal role in this sector is expected to double its annual revenue from data center interconnect products to $1 billion between fiscal 2026 and 2028, further solidifying its position in AI infrastructure.
See More
QVML Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: QVML's 52-week low is $35.06 per share, with a high of $44.815, and the last trade at $44.40 indicates the stock is fluctuating near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess price trends and identify potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing significant inflows or outflows, allowing assessment of their impact on underlying assets, particularly during the creation or destruction of units.
See More
Market Dynamics and Corporate Mergers Overview
- Muted Market Start: The new trading week begins with the S&P 500 indicated flat while the tech-heavy Nasdaq shows slight gains, and WTI crude oil is trading around $76.50 per barrel, reflecting cautious market sentiment regarding economic outlook.
- Abbvie Acquires Apogee: Abbvie is acquiring Apogee Therapeutics for $10.9 billion to strengthen its immunology portfolio, particularly competing with Johnson & Johnson's Tremfya through its top drug Skyrizi, which is expected to enhance Abbvie's competitive edge in the biopharmaceutical market.
- CRH Acquires Arcosa: CRH is acquiring Arcosa for $8.5 billion, stating that the acquisition is highly complementary amid growing demand for energy and utility infrastructure, which is expected to further solidify CRH's position in the construction materials market.
- Estee Lauder Buy Rating Reinstated: Goldman Sachs has reinstated a buy rating for Estee Lauder with a price target of $100, as analysts believe the market is underestimating the company's growth momentum, especially after it walked away from merger talks with Spanish beauty peer Puig.
See More
